跳至主要内容
临床试验/EUCTR2021-002214-14-DE
EUCTR2021-002214-14-DE招募中1 期

Individualized homeopathy to reduce the use of antibiotics in women with recurring uncomplicated urinary tract infections

Klinikum rechts der Isar, Technische Universität München0 个研究点目标入组 240 人开始时间: 2022年9月15日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1.Females, age <65 years
  • 2.Signed informed consent
  • 3.Documented recurrent UTI (i.e. = 2 UTI in 6 months and/ or = 3 UTI in 12 months)
  • 4.No change of other prophylactic treatment (e.g. Urovaxom, estrogen) for recurrent UTI for at least three months before baseline
  • 5.No product or dosage change of systemic hormonal treatment (including oral anticonception) for at least three months before baseline
  • 6.Female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 200
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 40

排除标准

  • 1.Individual symptomatology of the patient indicates the prescription of
  • a HMP which is not available within this clinical trial
  • 2.Pregnancy or breast feeding after pregnancy
  • 3.Women with a complicated urinary tract infection (including infections
  • occurring due to anatomical abnormalities (e.g. an obstruction, renal
  • tract calculi, hydro nephrosis), infections occurring due to an immune
  • compromised state (e.g. HIV, immune suppressive therapy), and
  • recurrent infections despite adequate treatment (multi-drug resistant
  • organisms or atypical organisms))
  • 4.Surgery of the urinary tract or the pelvic floor
  • 5.Known hypersensivity against the study medication or the
  • recommended on demand medication (Ibuprofen)
  • 6.Homoeopathic therapy for recurrent UTIs during the last 3 months
  • before baseline
  • 7.Postmenopausal woman WITHOUT previous attempt of a therapy
  • with locally applicate (vaginal) oestrogen
  • 8.Serious acute or chronic organic disease or serious mental disorder,
  • -diseases requiring immune suppressive therapy
  • -diabetes mellitus type 1 or 2 with an HbA1c > 7%
  • -any acute organic failure
  • -any advanced chronic organic failure (e.g. grade 3 or more)
  • -active cancer
  • -active (=clinically unstable) epileptic, cardiovascular or other organic
  • 9.Patients not able to declare meaningful informed consent on their own
  • (e.g. with legal guardian), or other vulnerable patients (e.g. under
  • 10.Simultaneous participation in any other clinical trial
  • 11.Employees or family members of the sponsor or investigators

研究者

相似试验